ImmunityBio, Inc.（股票代码：IBRX）今日盘前股价大幅上涨5.14%，引起了市场的关注。
消息面上，公司宣布已顺利完成一项关键性随机试验的患者招募工作，该试验旨在评估其核心产品Anktiva®联合卡介苗（BCG）对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。这一进展被视为公司在膀胱癌创新疗法开发领域的重要里程碑，增强了投资者对其研发管线未来潜力的信心，从而推动了股价上涨。
这项研究的完成为后续的数据分析和结果公布奠定了坚实基础，市场期待该疗法能为患者带来新的治疗选择，并可能为公司创造新的增长动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.